Recent Company News

• 08:32 AM ET Jul 09, 2026
  

  Quoin Pharmaceuticals receives FDA IND clearance to initiate Phase 2 study of QRX003 in peeling skin syndrome ($4.72, 0.00)

• 08:34 AM ET Jun 30, 2026
  

  Quoin Pharmaceuticals receives U.S. notice of allowance for patent covering combination treatment for Netherton syndrome ($4.55, 0.00)

• 08:33 AM ET Jun 23, 2026
  

  Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton syndrome ($4.41, 0.00)

• 08:34 AM ET Jun 18, 2026
  

  Quoin Pharmaceuticals completes establishment of Japanese subsidiary to advance commercial readiness for QRX003 ($4.62, 0.00)

• 08:36 AM ET Jun 16, 2026
  

  Quoin Pharmaceuticals provides clinical update from ongoing Pediatric Netherton Syndrome Compassionate Use Program ($4.65, 0.00)

• 06:31 AM ET Jun 15, 2026
  

  ThinkEquity initiates GLND, QNRX

• 02:40 PM ET Jun 12, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 14-June

• 01:55 PM ET Jun 05, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 7-June

• 08:35 AM ET Jun 04, 2026
  

  Quoin Pharmaceuticals announces Japan's MHLW grants orphan drug designation for QRX003 in Netherton syndrome ($4.43, 0.00)

• 08:33 AM ET Jun 02, 2026
  

  Quoin Pharmaceuticals submits IND application for QRX003 in Peeling Skin Syndrome ($4.77, 0.00)